-
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings Ocio EM, Mateos MV, Maiso P, Pandiella A, San Miguel JF. Lancet Oncology 9(12):1157-65. FI: 14.470 (Q1) Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired Martín-Ayuso M, Almeida J, Pérez-Andrés M, Cuello R, Galende J, González-Fraile MI, Martín-Nuñez G, Ortega F, Rodríguez MJ, San Miguel JF, Orfao A Oncologist 13(1):82-92 FI: 6.701 (Q1) PETHEMA Study Group, GEM Study Group. Prognostic value of immunophenotyping multiple myeloma: a study by the GEM and the PETHEMA cooperative study groups on patients uniformly treated with high dose therapy Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Díaz¿Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF. Journal of Clinical Oncology 26(16):2737-44. FI: 17.793 (Q1) Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma Rosinol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, González JD, Díaz-Mediavilla J, Hernández B, García-Frade J, Carrera D, Leon A, Hernández M, Fernández Abellán P, Bergua JM, San Miguel JF, Bladé J. Blood 112(9):3591-3. FI: 10.555 (Q1) Role of bortezomib for the treatment of previously untreated multiple myeloma Mateos MV. Expert Review of Hematology 1(1):17-28. FI: 2.493 (Q3) Should prophylactic granulocyte¿colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Mateos MV, García-Sanz R, Colado E, Olazabal J, San-Miguel JF British Journal of Haematology 140(3):324-6 FI: 4.597 (Q1) The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype Colado E, Álvarez¿Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF Haematologica 93(1):57-66 FI: 6.416 (Q1) The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells Maiso P, Ocio EM, Garayoa M, Montero JC, Hoffmann F, García-Echevarria C, Zimmermann J, Pandiella A, San Miguel JF. British Journal of Haematology 141(4):470-82 FI: 4.597 ¿Q1 The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease Alcoceba M, Marín L, Balanzategui A, Sarasquete ME, Martín-Jiménez P, Chillón MC, Corral R, Pérez-Persona E, Fernández¿Calvo FJ, Hernández JM, Bladé J, Lahuerta JJ, González M, San Miguel JF, García-Sanz R. Tissue Antigens 71(6):548-51. FI: 2.330 (Q3)
-
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC British Journal of Haematology 136(3):414-23 FI: 4.597 (Q1)
|
